Search

Search Results

• THE CLINICAL SIGNIFICANCE OF THE SPECTRUM OF INTERACTIONS OF THE RARE IVS-II-5 G>C (HBB: C.315+5 G>C) VARIATION WITH OTHER Β-THALASSEMIA MUTATIONS IN SOUTHERN CHINA

  Yali Zhou, Guiping Liao, Xiaolin Yin, Sheng He, Yi Wu, Jian Xiao, Zhili Geng, Qiuying Huang, Ganghui Luo, Kun Yang

  e2022034

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.034

  966

  PDF: 523

  HTML: 324

• A MULTICENTRE ICET-A STUDY OF CONFIRMED SARS-COV-2 INFECTION IN PATIENTS WITH HEMOGLOBINOPATHIES: PRELIMINARY DATA FROM 10 COUNTRIES

  Vincenzo De Sanctis

  e2020046

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.046

  2902

  PDF: 1584

  HTML: 314

• GENE THERAPY IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Laura Breda, Roberto Gambari, Stefano Rivella

  e2009008

  2009-11-16

  1293

  PDF: 428

  HTML: 2886

• POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia

  Vincenzo De Sanctis, Mohammad Faranoush, Efthymia Vlachaki, Theodora- Maria Venou, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025069

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.069

  516

  PDF: 253

  HTML: 43

• DOES INSULIN LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY HAVE A “PROTECTIVE” ROLE IN THE DEVELOPMENT OF DIABETIC RETINOPATHY IN THALASSEMIA MAJOR PATIENTS?

  Vincenzo De Sanctis

  e2015038

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.038

  1985

  PDF: 937

  HTML: 5067

• FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia

  Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Mohammad Faranoush, Ihab Elhakim, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis

  e2025072

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.072

  657

  PDF: 253

  Html: 33

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  1802

  PDF: 978

  HTML: 280

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2680

  PDF: 1394

  HTML: 308

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1179

  PDF: 428

  HTML: 166

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  2011

  PDF: 1455

  HTML: 231

• GLUCOSE METABOLISM AND INSULIN RESPONSE TO ORAL GLUCOSE TOLERANCE TEST (OGTT) IN PREPUBERTAL PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (TDT): A LONG-TERM RETROSPECTIVE ANALYSIS Long-term retrospective analysis of glucose homeostasis in children with transfusion dependent β-thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Ploutarchos Tzoulis, Shahina Daar, Salvatore Di Maio, Bernadette Fiscina, Christos Kattamis

  e2021051

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.051

  1754

  PDF: 552

  HTML: 167

• THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis

  Kun Yang, Jian Xiao

  e2024001

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.001

  1421

  PDF: 1436

  PDF: 1022

  HTML: 214

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1246

  PDF: 969

  HTML: 312

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1541

  PDF: 508

  HTML: 181

• CHARACTERISTICS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN MULTI-TRANSFUSED PATIENTS WITH THALASSEMIA MAJOR. EXPERIENCE OF A SINGLE TERTIARY CENTER.

  Nikolaos Papadopoulos, Dimitrios Kountouras, Katerina Malagari, Maria Tampaki, Maria Theochari, John Koskinas

  e2020013

  2020-02-26

  https://doi.org/10.4084/mjhid.2020.013

  1754

  PDF: 962

  HTML: 224

• CORRELATION OF TRANSIENT ELASTOGRAPHY WITH LIVER IRON CONCENTRATION, AND SERUM FERRITIN LEVELS IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA MAJOR PATIENTS FROM OMAN

  Hammad Khan, Vinodh Panjwani, Sara Al Rahbi, Abubakr Eltigani , Rizwan Qureshi, Khaleeq Unnisa, Najmus Sehar, Alok Mittal, Anil Pathare

  e2023048

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.048

  1109

  PDF: 697

  HTML: 204

• ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY

  Irene Motta, Valentina Brancaleoni, Isabella Nava, Paola Delbini, Lorena Duca

  e2020075

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.075

  1552

  PDF: 1423

  HTML: 514

• Impact of Donor-Specific anti-HLA antibodies and donor KIR characteristics in haploidentical HSCT for beta-Thalassemia

  Marco Andreani, Manuela Testi, Pietro Sodani, Maria Troiano, Andrea Di Luzio, Giuseppe Testa, Michela Falco, Elvira Poggi, Javid Gaziev, Antonina Piazza

  e2017020

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.020

  2988

  PDF: 976

  HTML: 532

• COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025050

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.050

  739

  PDF: 515

  HTML: 51

• IS HEMOGLOBIN E GENE WIDELY SPREAD IN THE STATE OF MADHYA PRADESH IN CENTRAL INDIA? EVIDENCE FROM FIVE TYPICAL FAMILIES

  R S Balgir

  e2014060

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.060

  1417

  PDF: 881

  HTML: 7981

  Untitled: 203

• PREVALENCE OF ß-THALASSEMIA MUTATIONS AMONG NORTHEASTERN IRANIAN POPULATION AND THEIR IMPACTS ON HEMATOLOGICAL INDICES AND APPLICATION OF PRENATAL DIAGNOSIS, A SEVEN-YEARS STUDY

  Mohammad Ehsan Jaripour, Kourosh Hayatigolkhatmi, Vahid Iranmanesh, Farhad Khadivi Zand, Zahra Badiei, Hamid Farhangi, Ali Ghasemi, Abdollah Banihashem, Reza Jafarzadeh Esfehani, Ariane Sadr-Nabavi

  e2018042

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.042

  2421

  PDF: 961

  HTML: 394

  Supplementary table 1: 228

  Some of the mutation detection samples: 217

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2652

  PDF: 1219

  HTML: 264

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4218

  PDF: 1460

  HTML: 609

• Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

  NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto

  e2022056

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.056

  1164

  HTML: 293

  PDF: 507

• EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR

  Kun Yang

  e2024076

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.076

  1070

  PDF: 583

  HTML: 150

• NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa

  Alessandro Matte, Filippo Mazzi, Enrica Federti, Oliviero Olivieri, Lucia De Franceschi

  e2019002

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.002

  6895

  PDF: 3664

  HTML: 773

• HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN ADULTS WITH SICKLE CELL DISEASE IN STEADY STATE: EXPERIENCE OF ONE FRENCH REFERENCE CENTER

  Giovanna Cannas, Solene Poutrel, Emilie Virot, Manon Marie, Alexandre Guilhem, Amal El-Kanouni, Richard Bourgeay, Marie-Grace Mutumwa, Mohamed Elhamri, Arnaud Hot

  e2025065

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.065

  995

  PDF: 533

  Html: 148

• DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA

  Sudhansu Sekhar Nishank

  e2015046

  2015-07-02

  https://doi.org/10.4084/mjhid.2015.046

  1567

  PDF: 794

  HTML: 1488

  Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 183

• IN UTERO HAEMATOPOIETIC STEM CELL TRANSPLANTATION (IUHSCT)

  Maria Concetta Renda, Aurelio Maggio

  e2009031

  2009-12-29

  1096

  PDF: 459

  HTML: 903

• THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.

  Ugo Testa, Giuseppe Leone, Prof. M.D. Cappellini

  e2024068

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.068

  2182

  PDF: 1315

  Html: 301

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2342

  PDF: 949

  HTML: 379

• SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM

  Zohreh Rahimi, Abbas Parsian

  e2011024

  2011-05-23

  https://doi.org/10.4084/mjhid.2011.024

  2274

  PDF: 901

  HTML: 2099

• Liver iron concentration and liver impairment in relation to serum IGF-1 levels in thalassaemia major patients: A retrospective study

  Vincenzo De Sanctis, Ashraf T Soliman, Giancarlo Candini, Christos Kattamis, Giuseppe Raiola, Heba Elsedfy

  e2015016

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.016

  1619

  PDF: 1038

  HTML: 854

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3143

  PDF: 1025

  HTML: 1655

• CURRENT ISSUES AND OPTIONS FOR HORMONAL CONTRACEPTION IN ADOLESCENTS AND YOUNG ADULT WOMEN WITH SICKLE CELL DISEASE: AN UPDATE FOR HEALTH CARE PROFESSIONALS Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease

  Vincenzo De Sanctis

  e2020032

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.032

  2213

  PDF: 1426

  HTML: 722